ストックスクリーナーアプリを入手
74.27
0.38%
0.28
アフターアワーズ：
75.15
0.88
+1.18%
前日終値:
$73.99
開ける：
$74.13
24時間の取引高:
2.34M
Relative Volume:
1.05
時価総額：
$14.31B
収益：
$217.77M
当期純損益:
$-438.86M
株価収益率:
-30.82
EPS:
-2.41
ネットキャッシュフロー:
$-456.33M
1週間 パフォーマンス:
-2.90%
1か月 パフォーマンス:
+0.86%
6か月 パフォーマンス:
+70.74%
1年 パフォーマンス:
+157.44%
1日の値動き範囲:
$72.89
$75.57
1週間の範囲:
$71.19
$78.58
52週間の値動き範囲:
$28.10
$78.58
Bridgebio Pharma Inc Stock (BBIO) Company Profile
BBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
74.27 | 14.26B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-11 | 開始されました | Bernstein | Outperform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-14 | 開始されました | Jefferies | Buy |
| 2025-07-09 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 開始されました | Wolfe Research | Outperform |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-03 | 開始されました | Oppenheimer | Perform |
| 2024-09-04 | 開始されました | Piper Sandler | Overweight |
| 2024-03-21 | 再開されました | Raymond James | Outperform |
| 2024-01-31 | 開始されました | BMO Capital Markets | Market Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-11-07 | 開始されました | Citigroup | Buy |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2023-04-19 | 開始されました | Evercore ISI | Outperform |
| 2023-02-06 | 開始されました | Cowen | Outperform |
| 2021-12-27 | 繰り返されました | Mizuho | Buy |
| 2021-12-27 | 繰り返されました | SVB Leerink | Outperform |
| 2021-09-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-03-22 | 繰り返されました | Goldman | Buy |
| 2021-02-22 | 再開されました | JP Morgan | Overweight |
| 2021-02-09 | 再開されました | Goldman | Buy |
| 2021-01-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-25 | 開始されました | BofA/Merrill | Neutral |
| 2020-05-19 | 開始されました | BTIG Research | Buy |
| 2020-04-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-19 | 開始されました | Mizuho | Buy |
| 2019-07-26 | 開始されました | Raymond James | Outperform |
| 2019-07-22 | 開始されました | BMO Capital Markets | Outperform |
| 2019-07-22 | 開始されました | Goldman | Buy |
| 2019-07-22 | 開始されました | JP Morgan | Overweight |
| 2019-07-22 | 開始されました | Jefferies | Buy |
| 2019-07-22 | 開始されました | Piper Jaffray | Overweight |
| 2019-07-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Bridgebio Pharma Inc (BBIO) 最新ニュース
Intratumoral Cancer Therapies Market Expected to Reach US$ - openPR.com
Is BridgeBio Pharma (BBIO) Pricing Reflect Long Term Potential After 156.5% One Year Surge - Yahoo Finance
BBIO's Analyst Rating: Morgan Stanley Initiates Coverage with Ov - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Morgan Stanley - MarketBeat
BridgeBio Pharma Has 20% Upside Growth Potential, Morgan Stanley Says - MarketScreener
Morgan Stanley Initiates BridgeBio Pharma at Overweight With $96 Price Target - marketscreener.com
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating By Investing.com - Investing.com Canada
Morgan Stanley initiates BridgeBio Pharma stock with Overweight rating - Investing.com India
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 6.5%Should You Sell? - MarketBeat
BridgeBio Pharma (BBIO) stock sinks 7% as JPM conference nears and achondroplasia catalyst looms - ts2.tech
BridgeBio to Participate in the J.P. Morgan Healthcare Conference - The Manila Times
BridgeBio Pharma stock hits all-time high at 78.46 USD By Investing.com - Investing.com Nigeria
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits all-time high at 78.46 USD - Investing.com
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET - The Manila Times
BridgeBio Pharma to Host Investor Webinar on Infigratinib and Achondroplasia Treatment Developments - Quiver Quantitative
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc.Common Stock (NQ: BBIO - FinancialContent
BridgeBio Pharma Earnings Notes - Trefis
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Behavioral Patterns of BBIO and Institutional Flows - Stock Traders Daily
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Aug Chart Watch: How BridgeBio Pharma Inc stock compares to industry benchmarksWeekly Trend Summary & Precise Trade Entry Recommendations - moha.gov.vn
BridgeBio Has More Room To Run (NASDAQ:BBIO) - Seeking Alpha
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma stock hits all-time high at $77.32 By Investing.com - Investing.com Nigeria
BridgeBio Pharma stock hits all-time high at $77.32 - Investing.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Why global investors buy BridgeBio Pharma Inc. (2CL) stockJuly 2025 Fed Impact & Low Risk Entry Point Guides - Улправда
Will BridgeBio Pharma Inc. stock benefit from commodity pricesTrade Entry Report & Real-Time Sentiment Analysis - Улправда
Why BridgeBio Pharma Inc. stock could rally in 20252025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
First Week of August 2026 Options Trading For BridgeBio Pharma (BBIO) - Nasdaq
What hedge fund activity signals for BridgeBio Pharma Inc. stock2025 Big Picture & Reliable Entry Point Trade Alerts - Улправда
Gains Recap: Why BridgeBio Pharma Inc. stock could rally in 2025Analyst Upgrade & Weekly Top Stock Performers List - Улправда
Will BridgeBio Pharma Inc. stock maintain growth story2025 Market Trends & Low Risk Growth Stock Ideas - Улправда
BridgeBio Pharma Sees Unusually Large Options Volume (NASDAQ:BBIO) - MarketBeat
Layoff Watch: What hedge fund activity signals for BridgeBio Pharma Inc. stockJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Path To Profitability - 富途牛牛
Hypoparathyroidism Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
BridgeBio Pharma Insider Sold Shares Worth $2,239,902, According to a Recent SEC Filing - MarketScreener
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares - MarketBeat
Pres Trimarchi Acquires 11,174 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (BBIO) CEO discloses RSU vesting and stock sales - Stock Titan
Officer Apuli Acquires 1,941 Of Bridgebio Pharma Inc [BBIO] - TradingView — Track All Markets
BridgeBio Pharma (NASDAQ: BBIO) CFO notes 13,826 shares withheld for taxes - Stock Titan
BridgeBio Pharma (BBIO) CAO discloses RSU tax share withholding - Stock Titan
BridgeBio Pharma (BBIO) Receives Maintained Rating with Raised P - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Hits New 12-Month HighTime to Buy? - MarketBeat
Is the Market Bullish or Bearish on BridgeBio Pharma Inc? - Benzinga
Bridgebio Pharma Inc (BBIO) 財務データ
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):